Assessing CONMED (CNMD) Valuation After A Mixed Stretch In Recent Share Performance

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

How CONMED Stock Has Been Trading Recently

CONMED (CNMD) has drawn attention after a mixed stretch in the share price, with a slight gain over the past month alongside declines over the past 3 months and year to date.

See our latest analysis for CONMED.

At a share price of $36.80, CONMED’s recent 30 day share price return of 5.78% contrasts with a weaker 90 day share price return of a 5.13% decline and a 1 year total shareholder return of a 34.92% decline, suggesting momentum has been fading rather than building.

If you are weighing up opportunities beyond medical technology stocks, this is a good moment to broaden your search with 17 top founder-led companies

With CONMED trading at $36.80 and metrics such as a value score of 5 and an indicated intrinsic discount of about 48%, it raises the key question: is this a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 24% Undervalued

With CONMED last closing at $36.80 against a narrative fair value of $48.40, the widely followed view points to a sizeable valuation gap built on cash flow expectations discounted at 9.17%.

Enhanced R&D investment supporting proprietary product innovation (e.g., next-gen BioBrace, PlumeSafe PX5), paired with a strengthened balance sheet and declining leverage, provides CONMED with both pricing power and financial flexibility, boosting the potential for sustained improvements in net margins and long-term earnings resilience.

Read the complete narrative.

The fair value is based on a clear formula that links projected revenue growth, margin uplift, and a future earnings multiple that sits below the broader medical equipment peer group. Want to see how those moving parts contribute to this valuation and how sensitive it is to small shifts in growth and profitability assumptions? The full narrative lays out the numbers behind that $48.40 figure.

Result: Fair Value of $48.40 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to keep an eye on supply chain setbacks in orthopedics and pressure on hospital capital budgets, which could challenge the optimistic margin outlook.

Find out about the key risks to this CONMED narrative.

Next Steps

With sentiment on CONMED split between concern over risks and optimism around potential rewards, it makes sense to review the data now, decide where you stand, and then weigh both sides with our 3 key rewards and 3 important warning signs

Story Continues

Looking for more investment ideas?

If CONMED is on your radar, do not stop there. The broader market holds plenty of other stocks that could better match your goals and risk comfort.

Target income potential and stability by checking out companies in the 13 dividend fortresses that focus on sustained cash returns. Hunt for potential mispriced opportunities using the 49 high quality undervalued stocks that filters for quality alongside attractive valuations. Prioritise resilience with the 72 resilient stocks with low risk scores tailored to highlight businesses with lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CNMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments